Cause specific mortality in #cirrhosis People with compensated disease or MASLD/NAFLD are often not dying from liver disease journals.lww.com/hepcomm/Fullte… I am so proud that Hepatology Communications gets to publish massive papers like this one from Jennifer Flemming #livertwitter

Grateful & excited to be a CIHR #VanierScholar for my ongoing graduate work in autoimmune liver disease epidemiology in Ontario inc. SES & exposome in devpt & prognosis! Many thanks to my mentors & pts who teach/humble/inspire me every day;can’t wait to pay it forward ➡️

Night time snack for #cirrhosis - Improves metabolism - Improves some outcomes - Increases muscle mass I enjoyed reading this review from Federico Ravaioli And so will you Paper (mdpi.com/2422550) has: 1. ALL THE DATA 2. Tailored recommendations #livertwitter #meded

Long term follow-up in pediatric autoimmune liver disease- interesting study with fascinating results. 🔑biliary disease may not present until later in some patients!

How to doctor - a thread.

What an honor to be able to hear from Dr Kamath about how to develop a successful career with joy and humility. Also being able to sit next to you and listen to the story of the Meld score was such an unique experience! Thanks for the opportunity @AutoImmuneLiver Aliya Gulamhusein

So proud of our University Health Network liver nurse team for evaluating our safety data on an RN-led paracentesis model for pts with decompensated cirrhosis for our poster @ #TLM2023! Well utilized in 🇬🇧 but 1st in 🇨🇦 🇺🇸 🇲🇽 Congrats Molly- 🏆 Poster of Distinction & AASLD Foundation awardee!

I'm so incredibly proud of my colleague who shined at The Liver Meeting, advocating passionately for patients with alcohol-related liver disease. ⁦AASLD⁩ ⁦AASLD Foundation⁩ ⁦Liz Lee⁩ ⁦@AutoImmuneLiver⁩⁩ ⁦⁦Hemant Shah⁩ Joanne Zee⁩

@AutoImmuneLiver excellent presentation highlighting positive study results. Great news for #PBC patients who need more treatment options that improve disease severity and quality of life. AASLD PBCers Organization

A UHN-led clinical trial has made a breakthrough in managing primary biliary cholangitis (PBC), a liver-related autoimmune disease with no known cure. Read more about the promising clinical trial led by #TeamUHN Physician Dr. Gideon Hirschfield ⬇ uhn.ca/corporate/news…

Congrats to Dr. Gideon Hirschfield and team for his spearheading a practice changing RCT on the role of Seladelpar in improving clinically relevant outcomes in patients with PBC with inadequate response to Ursodiol! Link below! nejm.org/doi/full/10.10…

EASL has released today a crucial position paper on the optimal management of patients cured of hepatitis C virus (HCV) following the advent of direct-acting antivirals (DAAs) covering: 🟢Follow-up for patients without advanced fibrosis, with compensated advanced chronic liver

Would you deny a therapy that increases 7-year survival from 13% to 64% ? If not, considering accepting EARLY liver TRANSPLANT for patients with Alcohol-related hepatitis. Great talk by Alexandre Louvet. #easlcongress #livertwitter Study of Alcohol-related LiVer disease in Europe EASL Education

*NEW SERIES* edited by Marina Serper, MD, MS @yucaspice Functional status is critical in determining outcomes in cirrhosis. Nutrition: journals.lww.com/cld/fulltext/2… Untangling sarcopenia, frailty, and fitness: journals.lww.com/cld/fulltext/2… Series link (when all published) journals.lww.com/cld/pages/coll…

It's been a long time coming! 1st paper from METCon_Consortium out now in Liver International! Read it here: onlinelibrary.wiley.com/doi/10.1111/li… Huge congrats team! So proud of all we accomplished and all we are looking forward to doing together! #Exercise #MASLD #LiverX Chris Pugh Daniel Cuthbertson

The best review on PSC that I have read journals.lww.com/hepcomm/fullte… Hepatology Communications

📌In our March issue Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial #OpenAccess here👉 journal-of-hepatology.eu/article/S0168-… #LiverTwitter